Skip to content
DataLookout
Menu

CAPTAINNCT06504056

Clinical Characteristics and Long-Term Outcomes of Left Ventricular Hypertrabeculation/Noncompaction

StatusRecruiting
PhaseNot specified
Primary completion (estimated)

At risk: Primary completion moved at least 23 years 3 months later, primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion dates pushed to Dec 31, 2050 Show 11 more changesShow less
    • Primary endpoint(s) modified
    • Recruitment opened
    • Enrollment increased: 2000 → 5000 participants
    • Eligibility criteria expanded, about 192 words
    • Interventions modified
    • Trial arms changed: 3 → 2
    • Start date changed from estimate of Oct 30, 2024 to Jul 20, 2024
    • Secondary endpoints expanded, about 92 words
    • Study description expanded, about 631 words
    • Site details revised
    • Study title shortened, about 3 words
  2. Minor Study description expanded, about 1 wordv2
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Time to First Major Adverse Clinical Event (Composite Outcome)
Timeframe: From baseline through 5 years

Secondary (13)

Number of Participants with All-Cause Mortality
Number of Participants with Cardiovascular Mortality
Number of Participants Hospitalized for New or Worsening Heart Failure
Number of Participants Experiencing Serious Ventricular Arrhythmias
Number of Participants Initiating Long-Term Mechanical Circulatory Support
Show 8 moreShow less
Number of Participants Undergoing Heart Transplantation
Number of Participants with New-Onset Atrial Fibrillation
Number of Participants with Ischemic Stroke or Systemic Thromboembolism
Number of Participants with Newly Detected Left Ventricular Thrombus
Number of Recurrent Heart Failure Hospitalizations
Change in Left Ventricular Ejection Fraction
Change in Noncompacted-to-Compacted Myocardial Thickness Ratio
Change in Left Ventricular End-Diastolic Dimension

Arms and interventions

Retrospective Cohort

Patients of all ages with imaging-confirmed left ventricular hypertrabeculation/noncompaction (LVHT/LVNC), identified from existing clinical records between January 1, 2018, and the date of ethics approval of the amended protocol. Retrospectively available demographic, clinical, imaging, laboratory, treatment, and follow-up data will be collected. Patients may have isolated LVHT/LVNC, associated cardiomyopathies, or other cardiac diseases and clinical conditions. Existing outcomes will be assessed using standardized definitions. No study-assigned interventions or additional clinical procedures will be performed.

Prospective Cohort

Patients of all ages with imaging-confirmed LVHT/LVNC, prospectively enrolled following ethics approval of the amended protocol through December 31, 2045. Participants may have isolated LVHT/LVNC, associated cardiomyopathies, or other cardiac diseases and clinical conditions. Baseline clinical and imaging information will be recorded, with follow-up planned at 6 months, 12 months, and annually from years 2 through 5. Clinical outcomes and longitudinal changes in cardiac structure and function will be assessed. Optional biospecimens may be collected during routine clinical care with appropriate consent. No study-assigned treatments or additional invasive procedures are required.

Sites

1 site in 1 country

  • First Affiliated Hospital of Xi'an Jiantong UniversityXi'an, Shaanxi, China